Infectious Disease

The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.

Steven Furr, MD, discusses how communication between clinicians and patients is crucial to combatting vaccine hesitancy this upcoming respiratory virus season.

Of the 25 routine lab tests studied, none proved clinically useful for diagnosing COVID-19, even among participants with a high long COVID symptom burden.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

HPV series initiation and completion was lower among adolescents seen at public vs private care settings and so was clinician guidance on vaccination in a new study.

Your daily dose of the clinical news you may have missed.

Patients largely underestimate how long a cold should last and the lingering symptoms too often prompt a request for antibiotics. Primary care, please resist!

The rate of ME/CFS was similar (3% to 4%) at 3 through 12 months for study participants who tested positive and negative for COVID-19.

Ziyad Al-Aly, MD, and colleagues link 70% of the drop in cases to vaccine availability but caution the risk for long COVID remains significant.

Researchers also found that a lower proportion of individuals were diagnosed with long COVID following reinfection than after initial infection.

The investigational live intranasal vaccine was safe and well-tolerated when given concomitantly with Fluzone HD and the combination outperformed the latter given by itself.

Tochi Iroku-Malize, MD, discusses the ACIP's updated recommendations for immunization against COVID-19, influenza, and RSV.

ICYMI: A quick look at 7 key drugs FDA-approved in the second quarter for conditions commonly seen in primary care.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

Individuals 6 months and older should receive updated COVID-19 and influenza vaccines for the 2024-2025 respiratory virus season, the agency recommended.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The investigational combination vaccine elicited higher immune responses vs licensed comparator vaccines in 2 independent age groups, the company said.

GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.

The over-the-counter antigen test, for use at home or at point of care, discriminates between SARS-CoV-2 and influenza A and B in 15 minutes.

Your daily dose of the clinical news you may have missed.

Data presented at ACOG 2024 suggest SARS-CoV-2 infection early in pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.

Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Details on educational gaps, vaccination rates, and the importance of an open dialogue between patients and clinicians, here.

While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

In STRIDE 10, V116 was superior to PPSV23 in adults aged ≥50 years and naive to pneumococcal vaccine for 8 of 9 serotypes unique to Merck's investigational shot.